Please note that due to a high volume of submissions, the ANZCTR is currently experiencing a delay in processing of submissions and updates.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03498716




Registration number
NCT03498716
Ethics application status
Date submitted
28/02/2018
Date registered
17/04/2018
Date last updated
9/01/2020

Titles & IDs
Public title
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Scientific title
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
Secondary ID [1] 0 0
2016-003695-47
Secondary ID [2] 0 0
WO39391
Universal Trial Number (UTN)
Trial acronym
IMpassion030
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Triple Negative Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Dose-dense Doxorubicin or dose-dense Epirubicin
Treatment: Drugs - Cyclophosphamide

Experimental: Atezolizumab + Chemotherapy - Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose
Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

Active Comparator: Chemotherapy - Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.
Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year

Treatment: Drugs: Paclitaxel
Paclitaxel will be administered by IV, 80 mg/m^2 every week for 12 weeks.

Treatment: Drugs: Dose-dense Doxorubicin or dose-dense Epirubicin
Dose-dense doxorubicin will be administered by IV, 60 mg/m^2 every 2 weeks for a total of 4 doses.
Or
Dose-dense epirubicin will be administered by IV, (90 mg/m^2) every 2 weeks for a total of 4 doses

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide will be administered by IV, 600 mg/m^2 every 2 weeks for 4 doses

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Invasive Disease-Free Survival (iDFS) - iDFS events are defined as follows:
Ipsilateral invasive breast tumor recurrence
Ipsilateral local-regional invasive breast cancer recurrence
Ipsilateral second primary invasive breast cancer
Contralateral invasive breast cancer
Distant recurrence
Death attributable to any cause
Timepoint [1] 0 0
Randomization until the first occurrence of iDFS event or death, through the end of study (approximately 7 years).
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Randomization to death from any cause through the end of study (approximately 7 years)
Secondary outcome [2] 0 0
Disease-Free Survival (DFS) - DFS is defined as any event of the primary endpoint and new diagnosis of an ipsilateral or contralateral non-invasive breast cancer.
Timepoint [2] 0 0
Randomization until the first occurrence of an DFS event, through the end of study (approximately 7 years)
Secondary outcome [3] 0 0
Recurrence-Free Interval (RFI)
Timepoint [3] 0 0
Randomization until local, regional, or distant disease recurrence of breast cancer, through the end of study (approximately 7 years)
Secondary outcome [4] 0 0
Distant RFI
Timepoint [4] 0 0
Randomization until distant disease recurrence, through the end of study (approximately 7 years)
Secondary outcome [5] 0 0
Percentage of participants with adverse events - Safety Objective
Timepoint [5] 0 0
Baseline to end of study (approximately 7 years)
Secondary outcome [6] 0 0
Serum concentration of Atezolizumab
Timepoint [6] 0 0
Pre-infusion (0 hour), 30 minutes post-infusion on Week 1 Day 1 (infusion length = 60 minutes); pre-infusion on Day 1 of Weeks 5, 9, 13, 21, 33 and 45; at treatment discontinuation (up to approximately 1 year), 120 days after last dose
Secondary outcome [7] 0 0
Invasive Disease-Free Survival (iDFS) in PDL1- Selected Patients
Timepoint [7] 0 0
Randomization until the first occurrence of iDFS event or death, through the end of study (approximately 7 years)
Secondary outcome [8] 0 0
Invasive Disease-Free Survival (iDFS) in Node- Positive Disease
Timepoint [8] 0 0
Randomization until the first occurrence of iDFS event or death, through the end of study (approximately 7 years)
Secondary outcome [9] 0 0
Invasive Disease Free Survival (iDFS) including second primary non-breast invasive cancer
Timepoint [9] 0 0
Randomization until the first occurrence of iDFS event or death, through the end of study (approximately 7 years)
Secondary outcome [10] 0 0
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab
Timepoint [10] 0 0
Updated: Pre-infusion (0 hour) on Day 1 of Weeks 1, 5, 9, 13, 21, 33 and 45; at treatment discontinuation (up to Week 51), 120 days after last dose
Secondary outcome [11] 0 0
Mean changes from baseline in patient-reported function (role, physical) - Mean changes from baseline score in role, physical function will be assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Core 30 (EORTC QLQ-C30)
Timepoint [11] 0 0
Baseline, Cycle 4 Day 1, Day 1 of every other cycle until Cycle 16 (cycle = 21 days), at the end of treatment/discontinuation visit ((up to approximately 1 year), and during Study Follow-up (up to approximately 7 years).
Secondary outcome [12] 0 0
Mean changes from baseline in patient-reported health-related quality of life (HRQoL) - Mean changes from baseline score in HRQoL will be assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire - Core 30 (EORTC QLQ-C30).
Timepoint [12] 0 0
Time Frame: Baseline, Cycle 4 Day 1, Day 1 of every other cycle until Cycle 16 (cycle = 21 days), at the end of treatment/discontinuation visit (up to approximately 1 year), and during Study Follow-up (up to approximately 7 years).

Eligibility
Key inclusion criteria
- Non-metastatic operable Stage II-III breast cancer

- Histologically documented TNBC (Triple Negative Breast Cancer)

- Confirmed tumor PD-L1 evaluation as documented through central testing of a
representative tumor tissue specimen

- Adequately excised: Patients must have undergone either breast-conserving surgery or
mastectomy/nipple- or skin-sparing mastectomy

- Adequate hematologic and end-organ function

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures and agreement to refrain from donating sperm.

- No more than 8 weeks (56 days) may elapse between definitive breast surgery and
randomization.

- Representative formalin-fixed, paraffin embedded (FFPE) tumor specimen from surgical
resection in paraffin blocks (preferred) or at least 25 unstained slides.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Prior history of invasive breast cancer

- For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment
(e.g., neoadjuvant or adjuvant), including, but not limited to, chemotherapy,
anti-HER2 therapy.

- Previous therapy with anthracyclines or taxanes for any malignancy

- Cardiopulmonary dysfunction

- Prior malignancies within 5 years prior to randomization, with the exception of those
with a negligible risk of metastasis or death and treated with expected curative
outcome

- Active or history of autoimmune disease or immune deficiency

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
chest computed tomography (CT) scan

- Urinary outflow obstruction

- Active tuberculosis

- Major surgical procedure other than for diagnosis within 4 weeks prior to initiation
of study treatment or anticipation of need for a major surgical procedure during study
treatment or within 5 months following the last dose of Atezolizumab (for patients
randomized to Atezolizumab)

- Prior allogeneic stem cell or solid organ transplant

- Treatment with systemic immunosuppressive medications within 2 weeks prior to
initiation of study treatment or anticipation of need for systemic immunosuppressive
medication during the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment hospital [2] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [3] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [4] 0 0
Lismore Base Hospital - Lismore
Recruitment hospital [5] 0 0
Northern Cancer Institute - St Leonards
Recruitment hospital [6] 0 0
Macquarie University Hospital - Sydney
Recruitment hospital [7] 0 0
Tweed Hospital - Tweed Heads
Recruitment hospital [8] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [9] 0 0
Icon Cancer Care Wesley - Auchenflower
Recruitment hospital [10] 0 0
Icon Cancer Foundation; Icon Cancer Care Chermside - Chermside
Recruitment hospital [11] 0 0
Icon Cancer Care South Brisbane - South Brisbane
Recruitment hospital [12] 0 0
Icon Cancer Foundation - South Brisbane
Recruitment hospital [13] 0 0
Mater Hospital; Cancer Services - South Brisbane
Recruitment hospital [14] 0 0
Icon Cancer Foundation; Icon Cancer Care Southport - Southport
Recruitment hospital [15] 0 0
Princess Alexandra Hospital; Cancer Trials Unit - Woolloongabba
Recruitment hospital [16] 0 0
Royal Adelaide Hospital; Cancer Centre - Adelaide
Recruitment hospital [17] 0 0
Ashford Cancer Center Research - Kurralta Park
Recruitment hospital [18] 0 0
Box Hill Hospital; Eastern Clinical Research Unit - Box Hill
Recruitment hospital [19] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [20] 0 0
Peninsula and South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [21] 0 0
Austin Hospital Olivia Newton John Cancer Centre - Heidelberg
Recruitment hospital [22] 0 0
Maroondah Hospital; Breast Clinic - Ringwood East
Recruitment postcode(s) [1] 0 0
2200 - Bankstown
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [4] 0 0
2480 - Lismore
Recruitment postcode(s) [5] 0 0
2065 - St Leonards
Recruitment postcode(s) [6] 0 0
2109 - Sydney
Recruitment postcode(s) [7] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [8] 0 0
2076 - Wahroonga
Recruitment postcode(s) [9] 0 0
4066 - Auchenflower
Recruitment postcode(s) [10] 0 0
4032 - Chermside
Recruitment postcode(s) [11] 0 0
4101 - South Brisbane
Recruitment postcode(s) [12] 0 0
4215 - Southport
Recruitment postcode(s) [13] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [14] 0 0
5000 - Adelaide
Recruitment postcode(s) [15] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [16] 0 0
3128 - Box Hill
Recruitment postcode(s) [17] 0 0
3168 - Clayton
Recruitment postcode(s) [18] 0 0
3199 - Frankston
Recruitment postcode(s) [19] 0 0
3084 - Heidelberg
Recruitment postcode(s) [20] 0 0
3135 - Ringwood East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Montana
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Dakota
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Utah
Country [21] 0 0
United States of America
State/province [21] 0 0
West Virginia
Country [22] 0 0
Argentina
State/province [22] 0 0
Berazategui
Country [23] 0 0
Argentina
State/province [23] 0 0
Ciudad Autonoma Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
La Rioja
Country [26] 0 0
Argentina
State/province [26] 0 0
Rosario
Country [27] 0 0
Argentina
State/province [27] 0 0
San Miguel de Tucuman
Country [28] 0 0
Argentina
State/province [28] 0 0
Viedma
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Innsbruck
Country [31] 0 0
Austria
State/province [31] 0 0
Linz
Country [32] 0 0
Austria
State/province [32] 0 0
Salzburg
Country [33] 0 0
Austria
State/province [33] 0 0
Vienna
Country [34] 0 0
Austria
State/province [34] 0 0
Vöcklabruck
Country [35] 0 0
Austria
State/province [35] 0 0
Wels
Country [36] 0 0
Belgium
State/province [36] 0 0
Brasschaat
Country [37] 0 0
Belgium
State/province [37] 0 0
Bruxelles
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Liège
Country [40] 0 0
Belgium
State/province [40] 0 0
Mons
Country [41] 0 0
Belgium
State/province [41] 0 0
Namur
Country [42] 0 0
Belgium
State/province [42] 0 0
Sint Niklaas
Country [43] 0 0
Brazil
State/province [43] 0 0
BA
Country [44] 0 0
Brazil
State/province [44] 0 0
CE
Country [45] 0 0
Brazil
State/province [45] 0 0
RJ
Country [46] 0 0
Brazil
State/province [46] 0 0
RS
Country [47] 0 0
Brazil
State/province [47] 0 0
SC
Country [48] 0 0
Brazil
State/province [48] 0 0
SP
Country [49] 0 0
China
State/province [49] 0 0
Beijing City
Country [50] 0 0
China
State/province [50] 0 0
Beijing
Country [51] 0 0
China
State/province [51] 0 0
Changchun
Country [52] 0 0
China
State/province [52] 0 0
Chengdu
Country [53] 0 0
China
State/province [53] 0 0
Chongqing
Country [54] 0 0
China
State/province [54] 0 0
Fujian
Country [55] 0 0
China
State/province [55] 0 0
Fuzhou
Country [56] 0 0
China
State/province [56] 0 0
Guangzhou City
Country [57] 0 0
China
State/province [57] 0 0
Guangzhou
Country [58] 0 0
China
State/province [58] 0 0
Hangzhou
Country [59] 0 0
China
State/province [59] 0 0
Harbin
Country [60] 0 0
China
State/province [60] 0 0
Jinan
Country [61] 0 0
China
State/province [61] 0 0
Nanjing
Country [62] 0 0
China
State/province [62] 0 0
Qingdao
Country [63] 0 0
China
State/province [63] 0 0
Shanghai City
Country [64] 0 0
China
State/province [64] 0 0
Shanghai
Country [65] 0 0
China
State/province [65] 0 0
Shenzhen City
Country [66] 0 0
China
State/province [66] 0 0
Shijiazhuang
Country [67] 0 0
China
State/province [67] 0 0
Wuhan City
Country [68] 0 0
China
State/province [68] 0 0
Xi'an City
Country [69] 0 0
China
State/province [69] 0 0
Zhengzhou
Country [70] 0 0
Czechia
State/province [70] 0 0
Horovice
Country [71] 0 0
Czechia
State/province [71] 0 0
Hradec Kralove
Country [72] 0 0
Czechia
State/province [72] 0 0
Olomouc
Country [73] 0 0
Czechia
State/province [73] 0 0
Prague
Country [74] 0 0
Czechia
State/province [74] 0 0
Praha 2
Country [75] 0 0
Czechia
State/province [75] 0 0
Zlin
Country [76] 0 0
Denmark
State/province [76] 0 0
Herlev
Country [77] 0 0
Denmark
State/province [77] 0 0
Naestved
Country [78] 0 0
Denmark
State/province [78] 0 0
Odense C
Country [79] 0 0
Denmark
State/province [79] 0 0
Vejle
Country [80] 0 0
France
State/province [80] 0 0
Ars-Laquenexy
Country [81] 0 0
France
State/province [81] 0 0
Avignon
Country [82] 0 0
France
State/province [82] 0 0
Beauvais
Country [83] 0 0
France
State/province [83] 0 0
Besançon
Country [84] 0 0
France
State/province [84] 0 0
Blois
Country [85] 0 0
France
State/province [85] 0 0
Bordeaux
Country [86] 0 0
France
State/province [86] 0 0
Bourg-en- Bresse Cedex
Country [87] 0 0
France
State/province [87] 0 0
Brest
Country [88] 0 0
France
State/province [88] 0 0
Caen
Country [89] 0 0
France
State/province [89] 0 0
Cholet
Country [90] 0 0
France
State/province [90] 0 0
Clermont Ferrand
Country [91] 0 0
France
State/province [91] 0 0
Compiegne
Country [92] 0 0
France
State/province [92] 0 0
Contamine Sur Arve
Country [93] 0 0
France
State/province [93] 0 0
Dijon
Country [94] 0 0
France
State/province [94] 0 0
Grenoble Cedex 9
Country [95] 0 0
France
State/province [95] 0 0
La Roche Sur Yon
Country [96] 0 0
France
State/province [96] 0 0
Le Chesnay
Country [97] 0 0
France
State/province [97] 0 0
Le Havre
Country [98] 0 0
France
State/province [98] 0 0
Limoges
Country [99] 0 0
France
State/province [99] 0 0
Lorient
Country [100] 0 0
France
State/province [100] 0 0
Lyon
Country [101] 0 0
France
State/province [101] 0 0
Marseille
Country [102] 0 0
France
State/province [102] 0 0
Mont De Marsan
Country [103] 0 0
France
State/province [103] 0 0
Montpellier
Country [104] 0 0
France
State/province [104] 0 0
Nantes
Country [105] 0 0
France
State/province [105] 0 0
Nice
Country [106] 0 0
France
State/province [106] 0 0
Orléans
Country [107] 0 0
France
State/province [107] 0 0
Paris
Country [108] 0 0
France
State/province [108] 0 0
Perigueux
Country [109] 0 0
France
State/province [109] 0 0
Plerin
Country [110] 0 0
France
State/province [110] 0 0
Pringy
Country [111] 0 0
France
State/province [111] 0 0
Quimper
Country [112] 0 0
France
State/province [112] 0 0
Reims
Country [113] 0 0
France
State/province [113] 0 0
Rennes
Country [114] 0 0
France
State/province [114] 0 0
Rouen
Country [115] 0 0
France
State/province [115] 0 0
St Priest en Jarez CEDEX
Country [116] 0 0
France
State/province [116] 0 0
Strasbourg
Country [117] 0 0
France
State/province [117] 0 0
Thonon Les Bains
Country [118] 0 0
France
State/province [118] 0 0
Toulouse
Country [119] 0 0
France
State/province [119] 0 0
Tours
Country [120] 0 0
France
State/province [120] 0 0
Valence
Country [121] 0 0
France
State/province [121] 0 0
Vandoeuvre-Les-Nancy
Country [122] 0 0
France
State/province [122] 0 0
Villejuif
Country [123] 0 0
France
State/province [123] 0 0
Villeneuve D Ascq
Country [124] 0 0
Germany
State/province [124] 0 0
Berlin
Country [125] 0 0
Germany
State/province [125] 0 0
Bremen
Country [126] 0 0
Germany
State/province [126] 0 0
Dortmund
Country [127] 0 0
Germany
State/province [127] 0 0
Dresden
Country [128] 0 0
Germany
State/province [128] 0 0
Erfurt
Country [129] 0 0
Germany
State/province [129] 0 0
Frankfurt
Country [130] 0 0
Germany
State/province [130] 0 0
Gütersloh
Country [131] 0 0
Germany
State/province [131] 0 0
Hildesheim
Country [132] 0 0
Germany
State/province [132] 0 0
Karlsruhe
Country [133] 0 0
Germany
State/province [133] 0 0
Köln
Country [134] 0 0
Germany
State/province [134] 0 0
Ludwigsburg
Country [135] 0 0
Germany
State/province [135] 0 0
Mainz
Country [136] 0 0
Germany
State/province [136] 0 0
Mannheim
Country [137] 0 0
Germany
State/province [137] 0 0
Mayen
Country [138] 0 0
Germany
State/province [138] 0 0
Minden
Country [139] 0 0
Germany
State/province [139] 0 0
Mönchengladbach
Country [140] 0 0
Germany
State/province [140] 0 0
München
Country [141] 0 0
Germany
State/province [141] 0 0
Neumarkt i.d.OPf.
Country [142] 0 0
Germany
State/province [142] 0 0
Ravensburg
Country [143] 0 0
Germany
State/province [143] 0 0
Stendal
Country [144] 0 0
Germany
State/province [144] 0 0
Tübingen
Country [145] 0 0
Germany
State/province [145] 0 0
Witten
Country [146] 0 0
Germany
State/province [146] 0 0
Worms
Country [147] 0 0
Hong Kong
State/province [147] 0 0
Hong Kong
Country [148] 0 0
Hong Kong
State/province [148] 0 0
Kowloon
Country [149] 0 0
Hungary
State/province [149] 0 0
Budapest
Country [150] 0 0
Hungary
State/province [150] 0 0
Miskolc
Country [151] 0 0
Hungary
State/province [151] 0 0
Pecs
Country [152] 0 0
Ireland
State/province [152] 0 0
Dublin
Country [153] 0 0
Ireland
State/province [153] 0 0
Galway
Country [154] 0 0
Ireland
State/province [154] 0 0
Limerick
Country [155] 0 0
Israel
State/province [155] 0 0
Haifa
Country [156] 0 0
Israel
State/province [156] 0 0
Jerusalem
Country [157] 0 0
Israel
State/province [157] 0 0
Kfar Sava
Country [158] 0 0
Israel
State/province [158] 0 0
Petach Tikva
Country [159] 0 0
Israel
State/province [159] 0 0
Rehovot
Country [160] 0 0
Italy
State/province [160] 0 0
Abruzzo
Country [161] 0 0
Italy
State/province [161] 0 0
Emilia-Romagna
Country [162] 0 0
Italy
State/province [162] 0 0
Friuli-Venezia Giulia
Country [163] 0 0
Italy
State/province [163] 0 0
Lazio
Country [164] 0 0
Italy
State/province [164] 0 0
Liguria
Country [165] 0 0
Italy
State/province [165] 0 0
Lombardia
Country [166] 0 0
Italy
State/province [166] 0 0
Piemonte
Country [167] 0 0
Italy
State/province [167] 0 0
Toscana
Country [168] 0 0
Italy
State/province [168] 0 0
Umbria
Country [169] 0 0
Italy
State/province [169] 0 0
Veneto
Country [170] 0 0
Japan
State/province [170] 0 0
Aichi
Country [171] 0 0
Japan
State/province [171] 0 0
Chiba
Country [172] 0 0
Japan
State/province [172] 0 0
Ehime
Country [173] 0 0
Japan
State/province [173] 0 0
Fukuoka
Country [174] 0 0
Japan
State/province [174] 0 0
Fukushima
Country [175] 0 0
Japan
State/province [175] 0 0
Hiroshima
Country [176] 0 0
Japan
State/province [176] 0 0
Hokkaido
Country [177] 0 0
Japan
State/province [177] 0 0
Hyogo
Country [178] 0 0
Japan
State/province [178] 0 0
Kagoshima
Country [179] 0 0
Japan
State/province [179] 0 0
Kanagawa
Country [180] 0 0
Japan
State/province [180] 0 0
Kyoto
Country [181] 0 0
Japan
State/province [181] 0 0
Okinawa
Country [182] 0 0
Japan
State/province [182] 0 0
Osaka
Country [183] 0 0
Japan
State/province [183] 0 0
Saitama
Country [184] 0 0
Japan
State/province [184] 0 0
Shizuoka
Country [185] 0 0
Japan
State/province [185] 0 0
Tokyo
Country [186] 0 0
Korea, Republic of
State/province [186] 0 0
Cheongju-si
Country [187] 0 0
Korea, Republic of
State/province [187] 0 0
Dongnam-gu, Cheonan-si
Country [188] 0 0
Korea, Republic of
State/province [188] 0 0
Gyeonggi-do
Country [189] 0 0
Korea, Republic of
State/province [189] 0 0
Incheon
Country [190] 0 0
Korea, Republic of
State/province [190] 0 0
Seoul
Country [191] 0 0
Korea, Republic of
State/province [191] 0 0
Suwon City
Country [192] 0 0
Korea, Republic of
State/province [192] 0 0
Ulsan
Country [193] 0 0
Korea, Republic of
State/province [193] 0 0
Wonju
Country [194] 0 0
Mexico
State/province [194] 0 0
Nuevo LEON
Country [195] 0 0
Mexico
State/province [195] 0 0
SAN LUIS Potosi
Country [196] 0 0
Mexico
State/province [196] 0 0
Yucatan
Country [197] 0 0
Mexico
State/province [197] 0 0
D.f.
Country [198] 0 0
Mexico
State/province [198] 0 0
Distrito Federal
Country [199] 0 0
Mexico
State/province [199] 0 0
Mexico City
Country [200] 0 0
Peru
State/province [200] 0 0
Arequipa
Country [201] 0 0
Peru
State/province [201] 0 0
Lima
Country [202] 0 0
Poland
State/province [202] 0 0
Gdansk
Country [203] 0 0
Poland
State/province [203] 0 0
Kraków
Country [204] 0 0
Poland
State/province [204] 0 0
Poznan
Country [205] 0 0
Poland
State/province [205] 0 0
Warszawa
Country [206] 0 0
Poland
State/province [206] 0 0
Lódz
Country [207] 0 0
Romania
State/province [207] 0 0
Bucharest
Country [208] 0 0
Romania
State/province [208] 0 0
Bucuresti
Country [209] 0 0
Romania
State/province [209] 0 0
Cluj Napoca
Country [210] 0 0
Romania
State/province [210] 0 0
Craiova
Country [211] 0 0
Russian Federation
State/province [211] 0 0
Jaroslavl
Country [212] 0 0
Russian Federation
State/province [212] 0 0
Kaluga
Country [213] 0 0
Russian Federation
State/province [213] 0 0
Kurgan
Country [214] 0 0
Russian Federation
State/province [214] 0 0
Moskovskaja Oblast
Country [215] 0 0
Russian Federation
State/province [215] 0 0
Sankt Petersburg
Country [216] 0 0
Russian Federation
State/province [216] 0 0
Arkhangelsk
Country [217] 0 0
Russian Federation
State/province [217] 0 0
Belgorod
Country [218] 0 0
Russian Federation
State/province [218] 0 0
Irkutsk
Country [219] 0 0
Russian Federation
State/province [219] 0 0
Ivanovo
Country [220] 0 0
Russian Federation
State/province [220] 0 0
Moscow
Country [221] 0 0
Russian Federation
State/province [221] 0 0
Novgorod Veliky
Country [222] 0 0
Russian Federation
State/province [222] 0 0
Omsk
Country [223] 0 0
Russian Federation
State/province [223] 0 0
Pyatigorsk
Country [224] 0 0
Russian Federation
State/province [224] 0 0
Rostov-na-donu
Country [225] 0 0
Russian Federation
State/province [225] 0 0
Saint-Petersburg
Country [226] 0 0
Russian Federation
State/province [226] 0 0
Samara
Country [227] 0 0
Russian Federation
State/province [227] 0 0
Saransk
Country [228] 0 0
Russian Federation
State/province [228] 0 0
Saratov
Country [229] 0 0
Russian Federation
State/province [229] 0 0
Sochi
Country [230] 0 0
Russian Federation
State/province [230] 0 0
St. Petersburg
Country [231] 0 0
Singapore
State/province [231] 0 0
Singapore
Country [232] 0 0
Spain
State/province [232] 0 0
Barcelona
Country [233] 0 0
Spain
State/province [233] 0 0
Castellon
Country [234] 0 0
Spain
State/province [234] 0 0
Guipuzcoa
Country [235] 0 0
Spain
State/province [235] 0 0
Islas Baleares
Country [236] 0 0
Spain
State/province [236] 0 0
LA Coruña
Country [237] 0 0
Spain
State/province [237] 0 0
Madrid
Country [238] 0 0
Spain
State/province [238] 0 0
Pontevedra
Country [239] 0 0
Spain
State/province [239] 0 0
Tarragona
Country [240] 0 0
Spain
State/province [240] 0 0
Tenerife
Country [241] 0 0
Spain
State/province [241] 0 0
Alicante
Country [242] 0 0
Spain
State/province [242] 0 0
Burgos
Country [243] 0 0
Spain
State/province [243] 0 0
Caceres
Country [244] 0 0
Spain
State/province [244] 0 0
Jaen
Country [245] 0 0
Spain
State/province [245] 0 0
Leon
Country [246] 0 0
Spain
State/province [246] 0 0
Malaga
Country [247] 0 0
Spain
State/province [247] 0 0
Murcia
Country [248] 0 0
Spain
State/province [248] 0 0
Sevilla
Country [249] 0 0
Spain
State/province [249] 0 0
Valencia
Country [250] 0 0
Spain
State/province [250] 0 0
Zaragoza
Country [251] 0 0
Switzerland
State/province [251] 0 0
Aarau
Country [252] 0 0
Switzerland
State/province [252] 0 0
Bern
Country [253] 0 0
Switzerland
State/province [253] 0 0
Lausanne
Country [254] 0 0
Switzerland
State/province [254] 0 0
Olten
Country [255] 0 0
Switzerland
State/province [255] 0 0
Zürich
Country [256] 0 0
Taiwan
State/province [256] 0 0
Changhua
Country [257] 0 0
Taiwan
State/province [257] 0 0
Kaoshiung City
Country [258] 0 0
Taiwan
State/province [258] 0 0
Liuying Township
Country [259] 0 0
Taiwan
State/province [259] 0 0
Taichung
Country [260] 0 0
Taiwan
State/province [260] 0 0
Tainan
Country [261] 0 0
Taiwan
State/province [261] 0 0
Taipei City
Country [262] 0 0
Taiwan
State/province [262] 0 0
Taipei
Country [263] 0 0
Taiwan
State/province [263] 0 0
Taoyuan City
Country [264] 0 0
Thailand
State/province [264] 0 0
Bangkok
Country [265] 0 0
Thailand
State/province [265] 0 0
Chiang Rai
Country [266] 0 0
Thailand
State/province [266] 0 0
Hat Yai
Country [267] 0 0
Thailand
State/province [267] 0 0
Khon Kaen
Country [268] 0 0
Thailand
State/province [268] 0 0
Muang Lampang
Country [269] 0 0
Ukraine
State/province [269] 0 0
KIEV Governorate
Country [270] 0 0
Ukraine
State/province [270] 0 0
Podolia Governorate
Country [271] 0 0
Ukraine
State/province [271] 0 0
Chernigiv
Country [272] 0 0
Ukraine
State/province [272] 0 0
Chernivtsi
Country [273] 0 0
Ukraine
State/province [273] 0 0
Dnipropetrovsk
Country [274] 0 0
Ukraine
State/province [274] 0 0
Kirovograd
Country [275] 0 0
Ukraine
State/province [275] 0 0
Kryvyi Rih
Country [276] 0 0
Ukraine
State/province [276] 0 0
Lutsk
Country [277] 0 0
Ukraine
State/province [277] 0 0
Lviv
Country [278] 0 0
Ukraine
State/province [278] 0 0
Odesa
Country [279] 0 0
Ukraine
State/province [279] 0 0
Sumy
Country [280] 0 0
Ukraine
State/province [280] 0 0
Uzhgorod
Country [281] 0 0
Ukraine
State/province [281] 0 0
Zaporizhzhya
Country [282] 0 0
United Kingdom
State/province [282] 0 0
Edinburgh
Country [283] 0 0
United Kingdom
State/province [283] 0 0
Glasgow
Country [284] 0 0
United Kingdom
State/province [284] 0 0
Huddersfield
Country [285] 0 0
United Kingdom
State/province [285] 0 0
Leeds
Country [286] 0 0
United Kingdom
State/province [286] 0 0
London
Country [287] 0 0
United Kingdom
State/province [287] 0 0
Manchester
Country [288] 0 0
United Kingdom
State/province [288] 0 0
Northwood
Country [289] 0 0
United Kingdom
State/province [289] 0 0
Nottingham
Country [290] 0 0
United Kingdom
State/province [290] 0 0
Peterborough
Country [291] 0 0
United Kingdom
State/province [291] 0 0
Stoke-On-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Breast International Group
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Alliance Foundation Trials (AFT)
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Frontier Science and Technology Research Foundation Inc (FS)
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab
in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or
epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed
by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in
patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Trial website
https://clinicaltrials.gov/show/NCT03498716
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: WO39391 www.roche.com/about_roche/roche_worldwide.htm
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. and Canada)
Fax 0 0
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03498716